Announcements
- Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
- Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
- Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
- Panbela Announces Poster Presentation at American Association for Cancer Research:
- Panbela Announces Transfer to OTCQB Market
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
More ▼
Key statistics
On Friday, Panbela Therapeutics Inc (X70:MUN) closed at 0.36, 0.56% above its 52-week low of 0.358, set on Jul 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.36 |
---|---|
High | 0.36 |
Low | 0.36 |
Bid | 0.34 |
Offer | 0.44 |
Previous close | 0.358 |
Average volume | 28.00 |
---|---|
Shares outstanding | 4.85m |
Free float | 4.85m |
P/E (TTM) | -- |
Market cap | 1.64m USD |
EPS (TTM) | -20.38 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:36 BST.
More ▼